Could a puff of inhaled insulin stop Exercise-Induced lows in type 1 diabetes?

NCT ID NCT06880835

Recruiting now Disease control Sponsor: Jaeb Center for Health Research Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether inhaled insulin (Afrezza) given with a meal is safer than a standard pump insulin bolus for preventing low blood sugar during exercise afterward. About 30 adults with type 1 diabetes who use automated insulin pumps will complete three exercise sessions in a clinic. The goal is to see if the inhaled insulin leads to fewer episodes of low blood sugar within 90 minutes of starting exercise.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inhaled technosphere insulin (Afrezza)
What this could lead to: If it works, this could offer a safer way to manage mealtime insulin before exercise, reducing the risk of dangerously low blood sugar.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Inhaled insulin can cause cough or lung irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Washington
RECRUITING

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.